Dr. Butler emphasizes the increasing prevalence of chronic itch in the aging population and details the significant physical, psychological, and healthcare system burdens it imposes. He also explores why chronic pruritus is often under-recognized and challenging to diagnose due to its multifactorial etiologies
In this webinar, Dr. Butler highlights the complexities of chronic pruritus in older adults, highlighting its prevalence, burden, and the underlying pathophysiological mechanisms, including the role of type 2 inflammation
Dr. Butler delves into the multifaceted biological mechanisms, including type 2 inflammation, that drive chronic pruritus in older adults. He explains how age-related changes contribute to epidermal barrier dysfunction, neuropathic damage, and immune decline, leading to chronic pruritus.
Dr. Butler explores how type 2 inflammation is a common underlying mechanism in several prevalent chronic pruritic skin conditions affecting the elderly, such as CPUO, AD, BP, and PN
In this webinar, Dr. Butler highlights the complexities of chronic pruritus in older adults, highlighting its prevalence, burden, and the underlying pathophysiological mechanisms, including the role of type 2 inflammation

Join Dr. Kim as he explores the pathogenesis of CSU and the mechanisms that promote itch in CSU. The complex interplay of type 2 inflammation in CSU is examined, offering insights into its unique challenges for patients and clinicians alike.

In this final video, Dr. Kim compares the shared and distinct pathophysiological features that drive itch in AD, PN, and CSU. He ties together the knowledge from earlier episodes, highlighting the similarities and differences in the mechanisms of itch across these diseases.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.